1. Home
  2. ANAB vs MXL Comparison

ANAB vs MXL Comparison

Compare ANAB & MXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$55.75

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo MaxLinear Inc.

MXL

MaxLinear Inc.

HOLD

Current Price

$17.37

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
MXL
Founded
2005
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2015
2009

Fundamental Metrics

Financial Performance
Metric
ANAB
MXL
Price
$55.75
$17.37
Analyst Decision
Buy
Buy
Analyst Count
11
5
Target Price
$74.64
$19.80
AVG Volume (30 Days)
587.2K
917.6K
Earning Date
03-03-2026
04-22-2026
Dividend Yield
N/A
N/A
EPS Growth
91.02
46.08
EPS
N/A
N/A
Revenue
$234,603,000.00
$478,596,000.00
Revenue This Year
N/A
$22.10
Revenue Next Year
$33.49
$10.70
P/E Ratio
N/A
N/A
Revenue Growth
157.01
N/A
52 Week Low
$15.40
$8.40
52 Week High
$68.39
$20.82

Technical Indicators

Market Signals
Indicator
ANAB
MXL
Relative Strength Index (RSI) 42.55 51.44
Support Level $52.68 $16.00
Resistance Level $57.70 $18.44
Average True Range (ATR) 4.06 0.84
MACD -1.35 0.07
Stochastic Oscillator 8.37 65.31

Price Performance

Historical Comparison
ANAB
MXL

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About MXL MaxLinear Inc.

MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.

Share on Social Networks: